Innate Pharma (IPHA) Receivables - Other (2017 - 2025)

Innate Pharma posted quarterly Receivables - Other of $657684.6 for Q4 2025, up 591.54% year-on-year from $95105.0 in Q4 2024, and up 591.54% on a QoQ basis from $95105.0 in Q4 2024.

Innate Pharma (IPHA) has 9 years of Receivables - Other data on file, last reported at $657684.6 in Q4 2025.

  • For the quarter ending Q4 2025, Receivables - Other rose 591.54% year-over-year to $657684.6; the trailing twelve-month figure through Dec 2025 stood at $657684.6 (up 591.54% YoY), and the FY2025 full-year result was $657684.6, up 591.54% from the prior year.
  • Receivables - Other for Q4 2025 stood at $657684.6, up from $95105.0 in the prior quarter.
  • Across five years, Receivables - Other topped out at $931192.4 in Q4 2021 and bottomed at $62235.1 in Q4 2022.
  • The 5-year median for Receivables - Other is $111897.8 (2023), against an average of $371623.0.
  • The widest annual swing landed in 2022, when Receivables - Other slumped 93.32%; it then soared 591.54% in 2025.
  • A 5-year view of Receivables - Other shows it stood at $931192.4 in 2021, then plunged by 93.32% to $62235.1 in 2022, then jumped by 79.8% to $111897.8 in 2023, then slipped by 15.01% to $95105.0 in 2024, then jumped by 591.54% to $657684.6 in 2025.
  • The last three Receivables - Other figures came in at $657684.6 (Q4 2025), $95105.0 (Q4 2024), and $111897.8 (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn
8 Evaxion A 65.44 Bn 65.42 Bn -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn
10 Innate Pharma 199.64 Mn 199.64 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 136,193.09
Dec 31, 2025 136,193.09
Dec 31, 2024 95,104.99
Dec 31, 2024 95,104.99
Dec 31, 2023 111,897.75
Dec 31, 2023 111,897.75
Dec 31, 2022 62,235.09
Dec 31, 2022 62,235.09
Dec 31, 2021 931,192.35
Dec 31, 2021 931,192.35
Dec 31, 2020 883,486.78
Dec 31, 2020 883,486.78
Dec 31, 2019 602,146.89
Dec 31, 2019 602,146.89
Dec 31, 2018 123.94 Mn
Dec 31, 2018 123.94 Mn
Dec 31, 2017 163,663.12
Dec 31, 2017 163,663.12